Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The G protein-activated inwardly rectifying potassium (GIRK) channel, frequently referred to in medical and pharmacological texts as the 'calcium-dependent inwardly rectifying potassium channel' [2, 3, 7, 12], is a class of ion channels (Kir3 subfamily) primarily expressed in the central nervous system and the heart [1, 13, 14]. These channels are crucial for the inhibitory control of neuronal excitability and the regulation of heart rate. Unlike most potassium channels that are voltage-gated, GIRK channels are directly activated by the Gβγ subunits of G proteins, which are released following the stimulation of Gi/o-coupled receptors such as mu-opioid, GABA-B, and muscarinic M2 receptors [5, 12, 14]. Upon activation, the channel permits the efflux of potassium ions, causing membrane hyperpolarization and effectively suppressing neuronal firing and neurotransmitter release [3, 7, 12]. This mechanism is central to the action of opioid analgesics, which exert their effects by opening GIRK channels in the pain-processing pathways of the spinal cord and brain [2, 3, 5, 12]. Because they play a pivotal role in the 'braking' system of the nervous system, GIRK channels are implicated in a wide array of conditions, including chronic pain, epilepsy, drug addiction, and psychiatric disorders like schizophrenia [11, 14, 15]. In the cardiovascular system, GIRK activation in the atria contributes to the slowing of the heart rate mediated by the parasympathetic nervous system [1, 13, 14]. Therapeutic modulation of these channels offers opportunities for treating neurological and cardiac diseases, although safety concerns such as respiratory depression and cardiac slowing remain significant challenges [12, 14].
Binding of agonists to Gi/o-coupled receptors, such as the mu-opioid receptor, triggers the dissociation of heterotrimeric G-proteins; the released Gβγ subunits then bind directly to the GIRK channel, increasing its open probability and potassium conductance, which induces membrane hyperpolarization and suppresses cellular excitability [2, 6, 12].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-activated inwardly rectifying potassium channel (GIRK).